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Glioblastoma multiforme (GBM) is the most frequent and 
malignant type of primary tumors of the central nervous 
system. Despite current advances in multimodal therapies, 
involving advanced surgery, radio- and chemotherapy, 
and the development of innovative targeted therapies the 
outcome for patients with GBM is nearly always fatal, with 
a median survival time of only 12–15 months (1). Various 
obstacles hamper development of effective therapies, 
including cellular and molecular heterogeneity, high 
proliferation rate, pervasive tumor cell infiltration, intensive 
angiogenesis, therapeutic resistance, and, not last, the lack 
of a full understanding of the pathobiology of the disease. 
I n c r e a s i n g  e v i d e n c e  s u p p o r t s  t h a t  t h e  G B M 
microenvironment has a tremendous influence over the 
tumor growth and spread (2). Indeed, GBM tumor cells 
can be exposed to diverse cellular niches (e.g., perivascular, 
hypoxic, perinecrotic), influenced by different cell 
populations and enriched with specific repertoires of signal 
molecules (growth factors, cytokines, chemokines, etc.). 
These environmental cues steer tumor cell fate, affecting 
quiescence, proliferation, survival and invasion (3). Several 
studies indicate that GBM cells and GBM-like stem cells 
(GSCs) are able to recruit different normal brain cells, such 
as microglia, astrocytes, endothelial and immune cells, and 
induce them to modify the tumor microenvironment with 
pro-tumoral signals (4,5).
Despite intensive studies over the past decade on the 
influence of GSC interactions with different normal brain 
cells have been observed in many settings and are known 
to contribute to crucial tumor properties in GBMs, it is 
unclear whether GBM cells contribute to GSC properties 
and/or vice versa. In a study in Cell Stem Cells, Wang et al. (6) 
reported that, by secreting distinct molecules, GSCs 
and differentiated GBM cells (DGC) form a molecular 
dialogue that serves a dual role in the GBM by promoting 
not only GSC stemness and survival, but also supporting 
DGC survival and secretion. In immunocompromised 
mice, after intracranial co-transplantation with patient-
derived GSCs with DGCs, the Authors first observed 
accelerated tumor growth and reduced survival compared 
to xenograft-bearing mice transplanted with GSCs alone 
or GSCs with fibroblasts, suggesting a contribution from 
the DGCs in GSCs tumorigenicity. Following experiments 
demonstrated that the brain-derived neurotrophic factor 
(BDNF), previously demonstrated to act as proliferative 
signal in GBM (7), was highly secreted by, and mRNA 
levels were up-regulated in DGCs compared to matched 
GSCs. The Authors then hypothesized that GSCs would 
express NTRK2 to mediate the paracrine effects of BDNF. 
In agreement, they found that the BDNF receptor NTRK2 
was upregulated in GSCs and was specifically expressed by 
tumor cells that were positive for the GSC marker SOX2. 
The Authors went on to evaluate the in vivo effect of BDNF 
and showed that orthotopic co-transplantation of GSCs and 
BDNF-depleted DGCs resulted in reduced tumor growth 
compared with both that of GSCs and BDNF-expressing 
DGCs. Moreover, BDNF transduction of GSCs revealed 
enhanced intracranial tumor growth and reduced survival 
outcome when compared to original GSCs. 
Further experiments revealed intriguing characteristics 
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of the DGC-GSCs interaction. First, BDNF induced the 
upregulation of the neurotrophic peptide VGF specifically 
in GSCs through activation of the PI3K-AKT signaling, 
and VGF was shown to be critical for GSC growth and 
stemness. Second, VGF promoted increased DGC viability 
and growth. Third, VGF-depleted GSCs intracranially 
transplanted into mice exhibited increased survival and the 
absence of tumors. 
These findings demonstrate that DGCs and GSCs 
impact each other in a reciprocal fashion via their 
production of BDNF and VGF, respectively. Indeed, 
this cross-talk promotes synergy amongst these cells 
and thereby amplifies the tumorigenic potential of the 
individual cell populations. As a result, this interconnection 
benefits the tumor, but also implies that therapies that 
down-regulate one population may also reduce the other 
cell populations. 
There are many strengths in the paper. However, it 
should be noted that the novel findings were based on data 
obtained in CD133+ GSCs. Although CD133 is classically 
associated with GSCs, it is also expressed in normal neural 
stem cells. Moreover, it has been shown that CD133− 
GSCs exhibit different growth properties and molecular 
profiles (8), and, when implanted in rat brains, are capable 
of inducing tumors and give rise to CD133+ cells (9). Thus, 
further research is needed to clarify the role of CD133− 
GSCs before future studies aimed at developing therapies 
that interfere with GSCs-DGCs interactions such that the 
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